Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Single-Arm Study of 20-valent Pneumococcal Conjugate Vaccine (Apexxnar) in Healthy Children 15 Months–17 Years
2019-003308-11Phase 3
- Sponsor
- Pfizer
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Streptococcus pneumoniae type 19A capsular polysaccharide antigen in pneumococcal disease, sponsored by Pfizer. Primary endpoint: Prompted local reactions within 7 days.
02
Drugs
Streptococcus pneumoniae type 19A capsular polysaccharide antigen
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2019-003308-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003308-11.